Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC. Morrow JJ, et al. Among authors: rubin bp. Nat Med. 2018 Feb;24(2):176-185. doi: 10.1038/nm.4475. Epub 2018 Jan 15. Nat Med. 2018. PMID: 29334376 Free PMC article.
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Bayles I, Krajewska M, Pontius WD, Saiakhova A, Morrow JJ, Bartels C, Lu J, Faber ZJ, Fedorov Y, Hong ES, Karnuta JM, Rubin B, Adams DJ, George RE, Scacheri PC. Bayles I, et al. J Clin Invest. 2019 Oct 1;129(10):4377-4392. doi: 10.1172/JCI127718. J Clin Invest. 2019. PMID: 31498151 Free PMC article.
Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC. Morrow JJ, et al. Among authors: rubin bp. Nat Med. 2018 Apr 10;24(4):525. doi: 10.1038/nm0418-525c. Nat Med. 2018. PMID: 29634688
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.
Morton AR, Dogan-Artun N, Faber ZJ, MacLeod G, Bartels CF, Piazza MS, Allan KC, Mack SC, Wang X, Gimple RC, Wu Q, Rubin BP, Shetty S, Angers S, Dirks PB, Sallari RC, Lupien M, Rich JN, Scacheri PC. Morton AR, et al. Among authors: rubin bp. Cell. 2019 Nov 27;179(6):1330-1341.e13. doi: 10.1016/j.cell.2019.10.039. Epub 2019 Nov 21. Cell. 2019. PMID: 31761532 Free PMC article.
Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC::DUX4 fusion in CIC-rearranged sarcomas: a study of 48 molecularly confirmed cases.
Macedo RT, Baranovska-Andrigo V, Pancsa T, Klubíčková N, Rubin BP, Kilpatrick SE, Goldblum JR, Fritchie KJ, Billings SD, Michal M, Švajdler M, Kinkor Z, Michal M, Dermawan JK. Macedo RT, et al. Among authors: rubin bp. Histopathology. 2025 Feb;86(3):423-432. doi: 10.1111/his.15341. Epub 2024 Oct 9. Histopathology. 2025. PMID: 39381843 Free PMC article.
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. Schuetze SM, et al. Among authors: rubin bp. Clin Cancer Res. 2024 Oct 15;30(20):4584-4592. doi: 10.1158/1078-0432.CCR-23-3817. Clin Cancer Res. 2024. PMID: 38446990 Clinical Trial.
296 results